NCT04197986
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04197986 |
| Title | Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations |
| Acronym | PROOF302 |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | QED Therapeutics, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BGR | BEL |
CKB BOOST